People: Mylan Inc (MYL.OQ)
MYL.OQ on NASDAQ Stock Exchange Global Select Market
33.99USD
4:00pm EDT
33.99USD
4:00pm EDT
Price Change (% chg)
$0.43 (+1.28%)
$0.43 (+1.28%)
Prev Close
$33.56
$33.56
Open
$33.73
$33.73
Day's High
$34.62
$34.62
Day's Low
$33.54
$33.54
Volume
1,261,976
1,261,976
Avg. Vol
1,207,109
1,207,109
52-wk High
$34.62
$34.62
52-wk Low
$22.51
$22.51
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Robert Coury |
52 | 2012 | Executive Chairman of the Board |
Rajiv Malik |
52 | 2013 | President, Director |
Heather Bresch |
43 | 2012 | Chief Executive Officer, Director |
Rodney Piatt |
60 | 2011 | Vice Chairman of the Board, Lead Independent Director |
John Sheehan |
52 | 2010 | Executive Vice President, Chief Financial Officer, Principal Financial officer |
Anthony Mauro |
40 | 2012 | President, North America |
Harry Korman |
55 | 2012 | Chief Operating Officer, Executive Vice President |
Daniel Rizzo |
50 | 2010 | Senior Vice President, Chief Accounting Officer, Corporate Controller |
Wendy Cameron |
53 | 2002 | Independent Director |
Robert Cindrich |
69 | 2011 | Independent Director |
Neil Dimick |
63 | 2005 | Independent Director |
Melina Higgins |
40 | 2013 | Independent Director |
Douglas Leech |
58 | 2000 | Independent Director |
Joseph Maroon |
72 | 2003 | Independent Director |
Mark Parrish |
57 | 2009 | Independent Director |
C. Todd |
79 | 2002 | Independent Director |
Randall Vanderveen |
62 | 2002 | Independent Director |
Biographies
| Name | Description |
|---|---|
Robert Coury |
Mr. Robert J. Coury is the Executive Chairman of the Board of Mylan Inc. Mr. Coury has served as Chairman of the Board of Mylan since May 2009, and as Executive Chairman since January 1, 2012. Prior to serving as Chairman, he served as Vice Chairman of the Board commencing in March 2002. Mr. Coury also served as Mylan’s Chief Executive Officer from September 2002 to December 31, 2011.Before joining Mylan, he was Chief Executive Officer and principal owner of Coury Consulting, L.P., a Pittsburgh, Pennsylvania corporate advisory firm that he founded in 1989. |
Rajiv Malik |
Mr. Rajiv Malik serves as the President, Director of Mylan Inc. Mr. Malik has served as Mylan’s President since January 1, 2012, before which he was Mylan’s Executive Vice President and Chief Operating Officer since July 2009, and Mylan’s Head of Global Technical Operations from January 2007 to July 2009. In addition to his oversight of day-to-day operations of the Company as President, Mr. Malik has been instrumental in identifying, evaluating and executing on business development opportunities, expanding and optimizing Mylan’s product portfolios and leveraging Mylan’s global research and development capabilities, among other important contributions. Previously, he served as Chief Executive Officer of Matrix Laboratories Limited (n/k/a Mylan Laboratories Limited) from July 2005 to June 2008. Prior to joining Matrix, he served as Head of Global Development and Registrations for Sandoz GmbH from September 2003 to July 2005. Prior to joining Sandoz, Mr. Malik was Head of Global Regulatory Affairs and Head of Pharma Research for Ranbaxy from October 1999 to September 2003. |
Heather Bresch |
Ms. Heather Bresch serves as the Chief Executive Officer, Director of Mylan Inc. Ms. Bresch has served as Mylan’s CEO since January 1, 2012. Throughout her 20-year career with Mylan, Ms. Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Ms. Bresch served as Mylan’s President from July 2009 and was responsible for the day-to-day operations of the Company. Before that, she served as Mylan’s Chief Operating Officer and Chief Integration Officer from October 2007 to July 2009. During her career, Ms. Bresch has championed initiatives aimed at improving product quality and removing barriers to patient access to medicine, including working to improve access to treatment for HIV/AIDS patients and better ensuring the quality of pharmaceutical products sold in the United States. |
Rodney Piatt |
Mr. Rodney L. Piatt, CPA, is Vice Chairman of the Board, Lead Independent Director of Mylan Inc. Since 1996, he has also been President and owner of Horizon Properties, a real estate and development company. Since 2003, Mr. Piatt has also served as Chief Executive Officer and Director of Lincoln Manufacturing Inc., a steel and coal manufacturing company. |
John Sheehan |
Mr. John D. Sheehan, C.P.A., is Executive Vice President, Chief Financial Officer, Principal Financial officer of Mylan Inc., since April 2010. Prior to joining Mylan, he served as Chief Financial Officer of Delphi Automotive LLP (“Delphi”). In addition to serving as the Chief Financial Officer for Delphi, Mr. Sheehan held several senior management positions, including chief restructuring officer, chief accounting officer and controller since joining that company in 2002. Prior to joining Delphi, Mr. Sheehan was a partner at KPMG LLP, a global professional accounting firm. |
Anthony Mauro |
Mr. Anthony Mauro serves as President, North America of Mylan Inc., since January 1, 2012. He has served as President of Mylan Pharmaceuticals Inc. since 2009. In his 15 years at Mylan, Mauro has held roles of increasing responsibility across the Company’s business units, including President of Mylan Pharmaceuticals Inc., Chief Operating Officer for Mylan Pharmaceuticals ULC in Canada, Vice President of Strategic Development, North America, and Vice President of Sales, North America. |
Harry Korman |
Mr. Harry A. Korman serves as Chief Operating Officer, Executive Vice President of Mylan Inc., since January 1, 2012. Prior to that, he was the Senior Vice President and President, North America of Mylan since October 2007. From February 2005 to December 2009, he served as President of Mylan Pharmaceuticals Inc. Since joining Mylan through its acquisition of UDL Laboratories in 1996, Mr. Korman has held several positions of increasing responsibility, including President of UDL and Vice President of Sales and Marketing for Mylan Pharmaceuticals. |
Daniel Rizzo |
Mr. Daniel C. Rizzo, Jr., CPA, is Senior Vice President, Chief Accounting Officer, Corporate Controller of Mylan Inc. Mr. Rizzo has served as the Company’s Corporate Controller since June 2006, and as principal financial officer from October 2009 to March 2010. He joined the Company as Vice President, Chief Accounting Officer and Corporate Controller in June 2006. Prior to that time, he served as Vice President and General Controller of Hexion Specialty Chemicals, Inc. from October 2005 to May 2006, and from September 1998 to September 2005 he served as Vice President and Corporate Controller (and principal accounting officer) at Gardner Denver, Inc. |
Wendy Cameron |
Ms. Wendy Cameron is Independent Director of Mylan Inc. Ms. Cameron has served as Director and Co-Owner of Cam Land LLC, a harness racing business in Washington, Pennsylvania, since January 2003. From 1981 to 1998, she was Vice President, Divisional Sales & Governmental Affairs, Cameron Coca-Cola Bottling Company, Inc. Ms. Cameron served as Chairman of the Washington Hospital Board of Trustees and of the Washington Hospital Executive Committee until she stepped down in 2012. She had been a member of the hospital’s Board of Trustees since 1997 and a member of the Washington Hospital Foundation Board since 1993. In addition to being a business owner and having held an executive position with one of the nation’s bottlers for nearly 20 years, Ms. Cameron’s 11-year tenure on the Mylan Board has come during a period of massive growth at the Company. |
Robert Cindrich |
The Honorable Robert J. Cindrich is Independent Director of Mylan Inc. Since February 2011, Mr. Cindrich has served as the President of Cindrich Consulting, LLC, a business and healthcare consulting company that advises clients on corporate governance, compliance, and business strategies. In May 2012, he joined the Board of Directors of Allscripts Healthcare Solutions, Inc., which provides healthcare information technology solutions. From 2004 through 2012, Mr. Cindrich served as a senior advisor to the Office of the President of the University of Pittsburgh Medical Center (“UPMC”), a global health enterprise. From 2004 through 2011, Mr. Cindrich was the Chief Legal Officer of UPMC. From 1994 through 2004, Mr. Cindrich served as a judge on the United States District Court for the Western District of Pennsylvania. Prior to that appointment, he was active as an attorney in both government and private practice, including positions as the Allegheny County Assistant Public Defender and Assistant District Attorney, and as the U.S. Attorney for the Western District of Pennsylvania. |
Neil Dimick |
Mr. Neil F. Dimick, CPA, is Independent Director of Mylan Inc., since 2005. Currently retired, Mr. Dimick previously served as Executive Vice President and Chief Financial Officer of Amerisource Bergen Corporation, a wholesale distributor of pharmaceuticals, from 2001 to 2002. From 1992 to 2001, he was Senior Executive Vice President and Chief Financial Officer of Bergen Brunswig Corporation, a wholesale drug distributor. Prior to that experience, Mr. Dimick served as a partner with Deloitte & Touche LLP for 8 years. Mr. Dimick also serves on the Boards of Directors of WebMD Health Corp., Thoratec Corporation, and Resources Connection, Inc. Mr. Dimick served on the Board of Directors of HLTh Corporation from 2002 to 2009, at which time it was merged into WebMD Health Corp. |
Melina Higgins |
Ms. Melina Higgins has been appointed as Independent Director of Mylan Inc. effective February 11, 2013. Currently retired, Ms. Higgins previously served as a Partner and Managing Director, and in other senior roles at Goldman Sachs during her nearly 20-year career at the firm. During her tenure at Goldman Sachs, Ms. Higgins served as a member of the Investment Committee of the Principal Investment Area, which oversaw and approved global private equity and private debt investments and was one of the alternative asset managers in the world. She also served as head of the Americas as well as co-chairperson of the Investment Advisory Committee for the GS Mezzanine Partners funds. She holds an M.B.A. from Harvard Business School and a B.A. from Colgate University. |
Douglas Leech |
Mr. Douglas J. Leech, CPA, is Independent Director of Mylan Inc., since 2000. Mr. Leech is the founder and principal of DLJ Advisors. From 1999 to 2011, he was Founder, Chairman, President and Chief Executive Officer of Centra Bank, Inc. and Centra Financial Holdings, Inc., prior to which he was Chief Executive Officer and President of Huntington National Bank. Mr. Leech is also on the Board of Directors of United Bankshares, Inc. Mr. Leech’s public accounting, audit and professional experience has provided him both financial and business experience and leadership experience. |
Joseph Maroon |
Dr. Joseph C. Maroon, M.D., is Independent Director of Mylan Inc., since 2003. Dr. Maroon is currently Professor, Heindl Scholar in Neuroscience and Vice Chairman of the Department of Neurosurgery, University of Pittsburgh Medical Center, and has held other positions at UPMC since 1998. He has also served as the team neurosurgeon for the Pittsburgh Steelers since 1981. From 1995 to 1998, Dr. Maroon was Professor and Chairman of the Department of Surgery at Allegheny General Hospital, and from 1984 to 1999 he was Professor and Chairman of the Department of Neurosurgery at Allegheny General Hospital. Dr. Maroon has earned numerous awards for his contributions to neurosurgery from various national and international neurological societies throughout his career, and patients travel from all over the world to seek his care. |
Mark Parrish |
Mr. Mark W. Parrish is Independent Director of Mylan Inc., since September 1, 2009. Mr. Parrish has served as Chairman and CEO of Trident USA Health Services, a provider of mobile X-ray and laboratory services to the long-term care industry, since 2008. Since January 2013, Mr. Parrish has served on the Board of Directors of Omnicell, Inc., a company that specializes in healthcare technology. From 2001 to 2007, Mr. Parrish held management roles of increasing responsibilities with Cardinal Health Inc. and its affiliates, including Chief Executive Officer of Healthcare Supply Chain Services for Cardinal Health from 2006 to 2007. Mr. Parrish also serves as President of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies, and senior adviser to Frazier Healthcare Ventures, a healthcare oriented growth equity firm. |
C. Todd |
Mr. C. B. Todd is Independent Director of Mylan Inc., since 1993. Currently retired, Mr. Todd served as President and Chief Operating Officer of Mylan from 2001 to 2002. From 1970 until his initial retirement from Mylan in 1999, he served Mylan in various capacities, including Senior Vice President (1987-1999), President, Mylan Pharmaceuticals (1991-1999), Senior Vice President, Mylan Pharmaceuticals (1987-1991), and Vice President-Quality Control, Mylan Pharmaceuticals (1978-1987). |
Randall Vanderveen |
Dr. Randall L. Vanderveen, Ph.D., R.Ph., is Independent Director of Mylan Inc., since March 1, 2002. Dr. Vanderveen has served as Dean, John Stauffer Decanal Chair of the School of Pharmacy, University of Southern California since September 2005. From 1998 to 2005, he served as Dean of the School of Pharmacy and Graduate School of Pharmaceutical Science and Professor of Pharmacy at Duquesne University, Pittsburgh, Pennsylvania, before which he was Assistant Dean and Associate Professor at Oregon State University, in Portland, Oregon from 1988 to 1998. Dr. Vanderveen has an pharmaceutical and academic background. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Robert Coury |
28,032,800 |
Rajiv Malik |
9,746,890 |
Heather Bresch |
9,960,240 |
Rodney Piatt |
-- |
John Sheehan |
4,278,230 |
Anthony Mauro |
-- |
Harry Korman |
3,220,950 |
Daniel Rizzo |
1,272,580 |
Wendy Cameron |
-- |
Robert Cindrich |
-- |
Neil Dimick |
-- |
Melina Higgins |
-- |
Douglas Leech |
-- |
Joseph Maroon |
-- |
Mark Parrish |
-- |
C. Todd |
946,700 |
Randall Vanderveen |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Robert Coury |
5,099,959 | 50,018,530 |
Rajiv Malik |
197,306 | 2,855,920 |
Heather Bresch |
348,815 | 4,561,120 |
Rodney Piatt |
0 | 0 |
John Sheehan |
0 | 0 |
Anthony Mauro |
0 | 0 |
Harry Korman |
119,059 | 1,459,590 |
Daniel Rizzo |
0 | 0 |
Wendy Cameron |
0 | 0 |
Robert Cindrich |
0 | 0 |
Neil Dimick |
0 | 0 |
Melina Higgins |
0 | 0 |
Douglas Leech |
0 | 0 |
Joseph Maroon |
0 | 0 |
Mark Parrish |
0 | 0 |
C. Todd |
360,000 | 4,250,830 |
Randall Vanderveen |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
BRESCH HEATHER M |
100 | $0.00 |
DIMICK NEIL F |
19,994 | $30.51 |
DIMICK NEIL F |
19,994 | $12.96 |
VANDERVEEN RANDALL L |
5,208 | $0.00 |
PARRISH MARK W |
5,208 | $0.00 |
DIMICK NEIL F |
5,208 | $0.00 |
TODD CLARENCE B |
5,208 | $0.00 |
PIATT RODNEY L |
5,208 | $0.00 |
MAROON JOSEPH C |
5,208 | $0.00 |
CINDRICH ROBERT J |
5,208 | $0.00 |
LEECH DOUGLAS J |
5,208 | $0.00 |
CAMERON WENDY |
5,208 | $0.00 |
SHEEHAN JOHN D |
20,322 | $0.00 |
SHEEHAN JOHN D |
9,428 | $28.70 |
SHEEHAN JOHN D |
5,333 | $0.00 |
SHEEHAN JOHN D |
2,474 | $28.70 |
TODD CLARENCE B |
1,686 | $29.42 |
BRESCH HEATHER M |
12,000 | $30.15 |
KORMAN HARRY A |
8,230 | $30.11 |
KORMAN HARRY A |
8,230 | $12.15 |
KORMAN HARRY A |
26,046 | $17.46 |
KORMAN HARRY A |
22,908 | $17.46 |
MAURO ANTHONY |
6,973 | $11.18 |
KORMAN HARRY A |
22,908 | $30.11 |
MAURO ANTHONY |
6,973 | $30.15 |

